- Conditions
- Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
- Interventions
- Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years to 55 Years · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Polycystic Ovary Syndrome, Hyperandrogenism
- Interventions
- Flutamide, Progesterone, estrace
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 13 Years to 17 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Breast Cancer, Metastasis
- Interventions
- Fulvestrant, Tamoxifen
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2012
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Fountain Valley, California • La Jolla, California + 21 more
- Conditions
- Cystic Fibrosis, Hypoestrogenism
- Interventions
- Transdermal estrogen, Progesterone
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 0 Years to 100 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Ganetespib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina
- Conditions
- HIV Infections
- Interventions
- Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
- Conditions
- Solid Tumors and Lymphomas
- Interventions
- Alobresib, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more
- Conditions
- Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Akt Inhibitor MK2206, Anastrozole, Fulvestrant, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy
- Interventions
- DR-1021, Mircette®, Kariva®
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Contraception
- Interventions
- Ulipristal Acetate, Combined Oral Contraceptive Pill
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ethinyl Estradiol and Norethindrone, Healthy Volunteers
- Interventions
- isavuconazole, Oral Contraceptive (ethinyl estradiol / norethindrone)
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 50 Years to 65 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Breast Cancer
- Interventions
- Tamoxifen, Anastrozole, Fulvestrant
- Drug
- Lead sponsor
- Priscilla McAuliffe
- Other
- Eligibility
- Female only
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Interventions
- Neratinib, Fulvestrant, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
- Conditions
- Overweight
- Interventions
- LY3437943, Ethinyl Estradiol, Drospirenone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- South Miami, Florida • San Antonio, Texas
- Conditions
- Menopausal Syndrome
- Interventions
- Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Prostate Cancer, Thromboembolism
- Interventions
- docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Ovarian Insufficiency
- Interventions
- Hormone Replacement Therapy, Combined Oral Contraceptives
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 14 Years to 45 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
- Interventions
- Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin
- Dietary Supplement · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 9
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib, Fulvestrant, Standard Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 55
- States / cities
- Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more
- Conditions
- Contraceptive Usage, Vaginal Epithelial Disruption
- Interventions
- Desogen (ethinyl estradiol and desogestrel), NuvaRing (ethinyl estradiol and etonogestrel)
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Obesity, Menopausal Syndrome
- Interventions
- Placebo injection, Depo Lupron/Aromatase inhibitor, Depo Lupron/placebo, placebo, Estrogen cream
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Perimenopause-Related Depression
- Interventions
- Estradiol, ER Beta Agonist, Placebo, Provera
- Drug · Other
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland